Incremental Predictive Value of the Oncotype Genomic Prostate Score for Adverse Pathology in Active Surveillance Candidates
The Prostate · 2026
DOI: 10.1002/pros.70129 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2026. Verfasst von Yu Ozawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: AdventHealth Global Robotics Institute, Celebration, Florida, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Watchful Waiting, Prostate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
Genomic prostate score (GPS) may aid clinical decision‐making for active surveillance. We assessed whether GPS adds predictive value beyond established clinical variables for adverse pathology at radical prostatectomy (RP) in active surveillance‐eligible patients.
Methods
We retrospectively analyzed 387 men with National Comprehensive Cancer Network very‐low‐ to favorable intermediate‐risk prostate cancer who underwent Oncotype DX testing followed by RP without active surveillance. Multivariable logistic regression models were constructed to develop prediction models for adverse pathology at RP (Grade Group ≥ 3 and/or ≥ pT3a), including clinical variables (age, PSA, PSA density, biopsy Grade Group 2 [vs. 1], and PI‐RADS 4/5) with and without GPS. Model performance was assessed using the AUC with 10‐fold cross‐validation and compared using DeLong's test, continuous net reclassification improvement (NRI), and decision curve analysis. The incremental predictive value of GPS was also separately evaluated in very low/low‐risk and favorable intermediate‐risk subgroups.
Results
GPS independently predicted adverse pathology ( p < 0.001). The addition of GPS increased the AUC from 0.69 to 0.73 (ΔAUC = 0.036; 95% CI: 0.006–0.065; p = 0.018) and improved reclassification (NRI 0.41, 95% CI: 0.20–0.61). Decision curve analysis demonstrated added net benefit at intermediate threshold probabilities (0.40–0.70), with limited benefit at low thresholds (0.0–0.40). Improvement was significant in the favorable intermediate‐risk subgroup (ΔAUC = 0.039; 95% CI: 0.011–0.124; p = 0.026) but not in the very low/low‐risk subgroup (ΔAUC = 0.018; 95% CI: −0.043–0.049; p = 0.20). Surgical selection bias was the main limitation.
Conclusions
In this RP cohort, GPS modestly improved prediction of adverse pathology beyond PSA density and MRI, with clinical utility primarily in favorable intermediate‐risk patients, where treatment decisions between active surveillance and definitive therapy are uncertain. These findings suggest selective, risk‐adapted application of GPS to guide treatment decision‐making. Validation in prospective, diverse cohorts is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AdventHealth Global Robotics Institute, Celebration, Florida, USA.
- Urology Department, University of Central Florida (UCF), Orlando, Florida, USA.
- Big and Open Data Innovation Laboratory (BODaI-Lab) and Data Methods and Systems Statistical, University of Brescia, Brescia, Italy.
ORCID-Profile: Yu Ozawa, Marco Sandri, Shady Saikali
Zitieren
APA
Ozawa, Y., Moschovas, M. C., Sandri, M., Sharma, R., Saikali, S., Rogers, T., & Patel, V. (2026). Incremental Predictive Value of the Oncotype Genomic Prostate Score for Adverse Pathology in Active Surveillance Candidates. The Prostate. https://doi.org/10.1002/pros.70129
Vancouver
Ozawa Y, Moschovas MC, Sandri M, Sharma R, Saikali S, Rogers T, et al. Incremental Predictive Value of the Oncotype Genomic Prostate Score for Adverse Pathology in Active Surveillance Candidates. The Prostate. 2026. doi:10.1002/pros.70129
BibTeX
@article{Ozawa2026,
author = {Ozawa, Yu and Moschovas, Marcio Covas and Sandri, Marco and Sharma, Rohan and Saikali, Shady and Rogers, Travis and Patel, Vipul},
title = {Incremental Predictive Value of the Oncotype Genomic Prostate Score for Adverse Pathology in Active Surveillance Candidates},
journal = {The Prostate},
year = {2026},
doi = {10.1002/pros.70129}
}
EUVIMED